Recently it has been documented that vitamin D has important functions in the human body that are unrelated to its primary effects in calcium homeostasis and bone mineralization. In clinical studies, paricalcitol - a low-calcemic vitamin D analogue - has been shown to decrease proteinuria, a marker of disease progression and cardiovascular risk in patients with chronic kidney disease (CKD). The purpose of this study is to investigate the effect of a paricalcitol on renal and cardiovascular variables in patients with moderate to severe CKD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
30
2 capsules of 1 microgram daily
2 capsules daily
Department of Medical Research
Holstebro, Holstebro, Denmark
plasma renin concentration
Time frame: 6 weeks
Urinary albumin excretion
Time frame: 6 weeks
GFR
Time frame: 6 weeks
Fractional excretion of sodium
Time frame: 6 weeks
Urinary excretion of aquaporin-2
Time frame: 6 weeks
Urinary excretion of ENaC-beta
Time frame: 6 weeks
Urinary excretion of NCC
Time frame: 6 weeks
Plasma concentration of aldosterone
Time frame: 6 weeks
Plasma concentration of angiotensin-II
Time frame: 6 weeks
Plasma concentration of ADH
Time frame: 6 weeks
Plasma concentration of atrial natriuretic peptide
Time frame: 6 weeks
Plasma concentration of brain natriuretic peptide
Time frame: 6 weeks
Plasma concentration of endothelin
Time frame: 6 weeks
24-hr ambulatory blood pressure
Time frame: 6 weeks
Central blood pressure
Time frame: 6 weeks
Pulse wave velocity
Time frame: 6 weeks
augmentation index
Time frame: 6 weeks
Plasma concentration of ionized calcium
Time frame: 6 weeks
Plasma concentration of phosphate
Time frame: 6 weeks
Plasma concentration of alkaline phosphatase
Time frame: 6 weeks
Plasma concentration of Parathyroid hormon
Time frame: 6 weeks
Plasma concentration of 25-hydroxy-vitamin D
Time frame: 6 weeks
Plasma concentration of ultrasensitive CRP
Time frame: 6 weeks
Plasma concentration of TNF-alpha
Time frame: 6 weeks
Plasma concentration of TGF-beta
Time frame: 6 weeks
Urinary excretion of calcium
Time frame: 6 weeks
Plasma concentration of ADMA
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.